Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion–Positive Sarcomas
In this study, we show seclidemstat has in vitro activity in multiple rare and aggressive sarcomas caused by FET fusion proteins. With 13 RNA sequencing experiments, including multiple FET-rearranged sarcoma cell lines, this dataset is a rich resource for those studying FET-rearranged sarcomas.
Authors
- Aundrietta D. Duncan (ORCID: https://orcid.org/0000-0002-1094-4844)
- Galen Rask (ORCID: https://orcid.org/0000-0002-6877-4796)
- Matthew V. Cannon (ORCID: https://orcid.org/0000-0002-3035-9490)
- Julia Selich‐Anderson
- Emily R. Theisen (ORCID: https://orcid.org/0000-0003-2923-1198)
- Ariunaa Bayanjargal (ORCID: https://orcid.org/0000-0003-3841-3241)
- Cenny Taslim (ORCID: https://orcid.org/0000-0003-3302-9099)
- Rachel D. Dreher (ORCID: https://orcid.org/0000-0002-9041-624X)
- Jesse C. Crow
Institutions
- Nationwide Children's Hospital (US)
- Esperion Therapeutics (United States) (US)
- Essa Pharma (United States) (US)
- The Ohio State University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0296
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nationwide Children's Hospital
- National Institutes of Health